EVOKE-02:SG联合帕博利珠单抗一线治疗转移性NSCLC的PD-L1分层队列结果
EVOKE-02是一项全球、开放标签、多队列2期研究,评估Sacituzumab Govitecan(SG)联合帕博利珠单抗一线治疗无驱动基因突变的转移性NSCLC。PD-L1 TPS≥50%队列(30例)的ORR为66.7%,中位PFS为13.1个月;TPS<50%队列(62例)的ORR为29.0%,中位PFS为7.0个月。Trop-2表达与疗效无关,≥3级TEAE发生率为76.1%。
要点
- PD-L1 TPS≥50%患者ORR达66.7%,中位PFS 13.1个月。
- PD-L1 TPS<50%患者ORR为29.0%,中位PFS 7.0个月。
- Trop-2表达水平未显示与SG联合帕博利珠单抗疗效相关。
核心结论
- SG联合帕博利珠单抗在转移性NSCLC一线治疗中显示出抗肿瘤活性,尤其在PD-L1 TPS≥50%患者中。
- 不良事件总体可控,与两种药物各自已知安全性一致。
研究设计与样本
- 全球、开放标签、多队列2期研究(EVOKE-02,NCT05186974)。
- 入组无既往系统性治疗且无可用驱动基因改变的成人转移性NSCLC患者。
- 治疗方案:SG 10 mg/kg静脉注射(第1、8天)联合帕博利珠单抗200 mg静脉注射(第1天),21天为一周期。
- 主要终点为独立评审委员会评估的客观缓解率(ORR),次要终点包括无进展生存期(PFS)和安全性。
- 数据截止2024年6月3日,PD-L1 TPS≥50%队列(A组)30例,PD-L1 TPS<50%队列(B组)62例。
主要发现
- A组ORR为66.7%(95%CI 47.2-82.7),B组ORR为29.0%(95%CI 18.2-41.9)。
- A组中位PFS为13.1个月(95%CI 6.7-未达到),B组中位PFS为7.0个月(95%CI 4.2-12.9)。
- Trop-2表达与SG联合帕博利珠单抗治疗的PFS或ORR改善无相关性。
- ≥3级治疗中出现的不良事件(TEAE)发生于70例(76.1%),最常见为中性粒细胞减少(17.4%)。
- 导致停用任何研究药物的TEAE发生于25例(27.2%)。
临床怎么用
- 对于PD-L1 TPS≥50%的转移性NSCLC患者,SG联合帕博利珠单抗可作为潜在的一线治疗选择。
- 治疗期间需监测中性粒细胞减少等不良事件,及时处理以降低停药风险。
局限性
- 本研究为单臂2期研究,样本量有限,结果需进一步随机对照试验验证。
- 未报告Trop-2表达与疗效相关性的具体统计数值。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: Sacituzumab govitecan (SG) is a Trop-2-directed antibody-drug conjugate previously studied in patients with pretreated metastatic NSCLC (mNSCLC). Here, we report the results of EVOKE-02 (NCT05186974), a global, open-label, multicohort phase 2 study of SG plus pembrolizumab as first-line treatment in patients with mNSCLC. METHODS: Adult patients without prior systemic mNSCLC treatment, and no actionable genomic alterations, received SG 10 mg/kg intravenously on days 1 and 8 plus pembrolizumab 200 mg intravenously on day 1 of 21-day cycles. The primary end point was objective response rate (ORR) per independent review committee, and secondary end points included progression-free survival (PFS) and safety. RESULTS: As of data cutoff (June 3, 2024), there were 30 patients with programmed death-ligand 1 (PD-L1) tumor proportion score (TPS) more than or equal to 50% (cohort A) and 62 patients with PD-L1 TPS less than 50% (cohort B). ORR (95% confidence interval) was 66.7% (47.2-82.7) for cohort A and 29.0% (18.2-41.9) for cohort B. Median (95% confidence interval) PFS was 13.1 (6.7-not reached) months for cohort A and 7.0 (4.2-12.9) months for cohort B. Trop-2 expression did not correlate with greater clinical efficacy (PFS, ORR) from treatment with SG plus pembrolizumab. Grade 3 or greater treatment-emergent adverse events (TEAEs) occurred in 70 patients (76.1%); the most common TEAE was neutropenia (17.4%). TEAEs leading to discontinuation of any study drug occurred in 25 patients (27.2%). CONCLUSIONS: SG plus pembrolizumab demonstrated activity as treatment for mNSCLC, especially in patients with PD-L1 TPS more than or equal to 50%. AEs were manageable and consistent with the known safety profile of each individual agent.
引用
- Reck M, Patel JD, Gray JE, et al. First-Line Sacituzumab Govitecan Plus Pembrolizumab in Metastatic NSCLC: PD-L1 TPS Less Than 50% and More Than or Equal to 50% Cohorts of the EVOKE-02 Study. J Thorac Oncol. 2025. PMID: 41173143. doi:10.1016/j.jtho.2025.10.016
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。